Mailing address: P.O. Box 3207, Redondo Beach, CA 90277
e-mail: research@technomedics.net
Telephone: (310) 316-7757
Pager: (310) 768-9439

Manfred Mosk, Ph.D. is the President of Technomedics Management & Systems, Inc., a life sciences consulting firm. Dr. Mosk is the co-founder and a Director of ImmunoCellular Therapeutics, Ltd., OncoTx, Inc. and BioOncologics, Inc. companies, each of which are engaged in the research and development of proprietary novel drugs for the treatment of certain solid tumors. He serves as a member of the Board of Governors of Cedars Sinai Medical Center.

Dr. Mosk served as the Chairman of Duska Therapeutics, Inc. (ATP based drugs), and a Director of Arbios, Inc. (devices for the treatment of liver failure), California State University Foundation, UCLA’s Jonsson Cancer Center Foundation, College of Naturopathic Medicine and as Economic Counselor, Eastern European Division, Pfizer Inc.

As co-founder, President and CEO of Medco Research, Inc., this company clinically developed and obtained FDA approval to market the first adenosine based drugs for the treatment of paroxysmal supraventricular tachycardia (Adenocard) and the pharmacological stressor (Adenoscan) which is used in conjunction with cardiac imaging for the detection of coronary artery disease. Medco Research, Inc. was acquired by King Pharmaceuticals, Inc.

Dr. Mosk holds B.S., M.S. and Ph.D. degrees in business administration from California State University and California Western University and CW in pharmacology from The Institute for Applied Pharmaceutical Sciences. He is a member of the New York Academy of Sciences, the International Society of Pharmacoeconomics and Outcomes Research, the American Heart Association, the International Society of Stem Cell Research, the National Kidney Foundation, the American Society of Health Economists and the National Association of Business Economists.

Dr. Mosk is a director of University Kidney Research Organization.